51 reports of this reaction
3.7% of all METHYLERGONOVINE MALEATE reports
#2 most reported adverse reaction
DRUG EXPOSURE DURING PREGNANCY is the #2 most commonly reported adverse reaction for METHYLERGONOVINE MALEATE, manufactured by Lupin Pharmaceuticals,Inc.. There are 51 FDA adverse event reports linking METHYLERGONOVINE MALEATE to DRUG EXPOSURE DURING PREGNANCY. This represents approximately 3.7% of all 1,362 adverse event reports for this drug.
Patients taking METHYLERGONOVINE MALEATE who experience drug exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG EXPOSURE DURING PREGNANCY is moderately reported among METHYLERGONOVINE MALEATE users, representing a notable but not dominant share of adverse events.
In addition to drug exposure during pregnancy, the following adverse reactions have been reported for METHYLERGONOVINE MALEATE:
The following drugs have also been linked to drug exposure during pregnancy in FDA adverse event reports:
DRUG EXPOSURE DURING PREGNANCY has been reported as an adverse event in 51 FDA reports for METHYLERGONOVINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG EXPOSURE DURING PREGNANCY accounts for approximately 3.7% of all adverse event reports for METHYLERGONOVINE MALEATE, making it one of the most commonly reported side effect.
If you experience drug exposure during pregnancy while taking METHYLERGONOVINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.